Mr. Pratap Sandhu reports

THE PRECISION PEPTIDE COMPANY INC. RECEIVES 20,000-UNIT PRODUCTION RUN OF BPC-157 TRANSDERMAL PATCHES

The Precision Peptide Company Inc. has received its production run of approximately 20,000 units of its BPC-157 transdermal patch, the company's lead product candidate. The arrival of this commercial inventory follows the company's previously announced order and represents a key step in the company's transition from testing and formulation validation to commercialization.

Highlights

• Received full production run of approximately 20,000 BPC-157 transdermal patches, the company's lead product candidate;
• Patches are manufactured and independently tested in the United States;
• Marks the company's transition from testing to commercialization;
• Each patch delivers two milligrams of BPC-157, consistent with the 95.5-per-cent purity and 2.02-milligram dose.

The patch is proudly manufactured in the United States and was independently tested by a U.S. analytical laboratory. Each patch is formulated to deliver two mg of BPC-157, consistent with the third party test results reported in the company's previous news release, which confirmed 95.5-per-cent chromatographic purity, exceeding the greater than or equal to 95-per-cent threshold that is widely recognized across the peptide industry as the analytical benchmark for high-purity grade peptide products and a quantified dose of 2.02 mg of BPC-157 per patch.

With commercial inventory now in hand, the company is positioned to proceed toward the initial commercial release of the patch through The Precision Peptide Company website.

Pratap Sandhu, chief executive officer of The Precision Peptide Company, commented: "We are proud that our patches are made and tested right here in the U.S. That reflects the standard we've set for ourselves and for our customers. We ordered 20,000 units and they've now arrived, which moves us into fulfilment as we prepare to begin selling through our website."

About The Precision Peptide Company Inc.

The Precision Peptide is a publicly traded wellness company building a next-generation platform for high-quality peptide formulations. By combining scientific formulation and innovative delivery technologies, the company creates products at the intersection of biotechnology and scalable consumer wellness. Products are manufactured in an approved U.S. facility and distributed across North America.

We seek Safe Harbor.